An interventional study of Multi-component facilitation in Serious Mental Illness and Tobacco Use Disorder, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Tobacco Use Disorder by VA Office of Research and Development — 5 open to participants now, 6 under way, none of them phase 3. Tobacco Use Disorder · VA Office of Research and Development.
Among the 17 studies in Tobacco Use Disorder by VA Office of Research and Development, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, and was the 16th registered.
1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
Browse Tobacco Use Disorder studies →5 of the 17 studies in Tobacco Use Disorder by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 21+
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18–75
VA Office of Research and Development · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 65 is below the median of 90 across 893 interventional studies indexed under Tobacco Use Disorder.
Median enrollment 128 across the 16 interventional studies, 109 across the 1 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
2 of the studies in Tobacco Use Disorder by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03477435VA Office of Research and DevelopmentComparing an Opt-out to an opt-in Approach for Smoking Cessation in VA Primary Care Clinics | 2027-04-01 |
| NCT05723588VA Office of Research and DevelopmentNeuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Tobacco Use Disorder by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Smoking disproportionally impacts Veterans, and VA spends $2.7 billion annually on smoking-related health conditions. Veterans with serious mental illness (SMI) smoke tobacco products at triple the rate of Veterans without any mental illness and die 10-15 years earlier as a result. SMI Veterans who smoke want to quit and FDA-approved tobacco cessation medications are safe, effective, and readily available in VA. However, mental health providers are hesitant to treat smoking and just 11-18% of Veterans with SMI who smoke receive tobacco medication. External facilitation is an effective implementation strategy that can overcome barriers to integrating evidence-based treatment into routine clinical practice. In collaboration with local and operational partners, the proposed CDA-2 will evaluate and refine an external facilitation strategy to improve tobacco medication prescribing in VA SMI clinics. This proposal aligns with VA priorities to enhance timely access to care and improve Veteran outcomes.
Tobacco smoking and its health consequences disproportionally impact Veterans. Veterans with serious mental illness (SMI Veterans; schizophrenia spectrum, bipolar spectrum, and other psychotic disorders) have among the highest rates of smoking in VA and die 10-15 years earlier than those without SMI, largely due to smoking-related conditions. Seven FDA-approved tobacco medications are available in VA that are low-cost, safe, and effective for SMI Veterans when combined with brief behavioral counseling: nicotine replacement therapies (lozenge, gum, patch, nasal spray), bupropion, and varenicline. Nearly 70% of SMI Veterans who smoke want to quit, but they are 26% less likely to be prescribed tobacco medication (10.9% vs. 14.3% prescription rate) and also less likely to be advised to quit by physicians. SMI providers face numerous barriers to treating smoking. Implementation activities like external facilitation can address these barriers by coordinating other evidence-based implementation activities, such as academic detailing and auditing with feedback, that are tailored to local needs and show promise for improving tobacco treatment delivery in VA mental health clinics. Despite the availability of tobacco treatment in VA, smoking-related conditions remain the leading cause of death for SMI Veterans and account for nearly 8% of VA health care expenditures: $2.7 billion annually. Using external facilitation and other implementation strategies can help integrate tobacco treatment into routine mental health care and, in turn, reduce a critical health disparity between Veterans with and without SMI and maximize the VA's use of existing resources. The primary purpose of this study is to evaluate the acceptability and feasibility of this multi-component implementation strategy designed to improve tobacco treatment delivery in VAMHCS SMI clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Providers:
Veterans receiving direct letters:
Appointment scheduled with an outpatient psychiatric prescriber in the next 30 days
Veteran chart review:
All Veterans actively enrolled in VAMHCS medical facilities with at least one encounter during a given period with available smoking health factor data
Exclusion Criteria:
Providers:
Veterans receiving direct letters:
The facilitation strategy will involve an external facilitator who will support other implementation activities: educational outreach, auditing performance and providing feedback, training, Veteran outreach, champions, and implementation team meetings.
Other: Multi-component facilitation
Facilitation includes identifying multilevel barriers to change, selecting implementation activities to address known barriers, tailoring implementation activities to the local context, providing social support, problem-solving challenges, conducting administrative duties, and refining implementation activities over time in response to data-driven needs for improvement. Facilitation will support multiple other evidence-based implementation activities like auditing performance with feedback and engaging patients. The proposed study will use an external facilitator - someone outside the clinic with expertise in implementation science and tobacco treatment - to partner with clinic representatives and operational leaders who share a commitment to increasing adoption of tobacco medication.
Semi-structured, one-on-one interviews
Acceptability and feasibility: Interviews will gauge provider satisfaction with the implementation strategy (acceptability) and provider perceptions of the actual fit of the implementation strategy with the clinical setting (feasibility). This qualitative data will be analyzed for common themes. The number of providers endorsing each theme will be quantified.
Time frame: 12 months after start of implementation at each site
Implementation tracker
Based on observation, the investigators will track provider attendance at trainings (number of providers attending divided by total number of eligible providers) and number of academic detailing sessions completed per provider (minimum = 1, maximum = 3) in an excel spreadsheet as benchmarks of feasibility to inform refinements to the implementation strategy.
Time frame: Weekly for the duration of the implementation at each site (12 months)
Smoking Knowledge, Attitudes, and Practices Scale: Practices subscale only
Adoption: The survey will inquire about provider frequency of delivering evidence-based tobacco treatment to Veterans. Minimum = 0 (never), maximum = 4 (always). A higher score is desired because it suggests frequent tobacco treatment delivery.
Time frame: Before implementation, at end of implementation (12 months), and 12 months after end of implementation (24 months)
Prescriptions of tobacco cessation medication
Reach: Change in the proportion of eligible Veterans prescribed a medication for tobacco use from the VHA corporate data warehouse.
Time frame: Monthly 12 months before through 12 months after the end of implementation (36 months)
Changes in tobacco use
Effectiveness: Changes in the proportion of Veterans quitting tobacco from the VHA corporate data warehouse.
Time frame: Monthly 12 months before through 12 months after the end of implementation (36 months)
Plan to share: Yes — Person-level qualitative data from semi-structured interviews can be provided as a de-identified, anonymized dataset depending on the need of the requester pursuant to a Data Use Agreement appropriately limiting use of the dataset and prohibiting the recipient from identifying, or taking steps to re-identify, any individuals whose data are included in the dataset. Audio recordings of qualitative interviews will not be shared. For chart review data, a Limited Dataset will be created and shared pursuant to a Data Use Agreement appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available for sharing starting 6 months after publication.
Access criteria: Person-level qualitative data from semi-structured interviews can be provided as a de-identified, anonymized dataset depending on the need of the requester pursuant to a Data Use Agreement appropriately limiting use of the dataset and prohibiting the recipient from identifying, or taking steps to re-identify, any individuals whose data are included in the dataset. Audio recordings of qualitative interviews will not be shared. For chart review data, a Limited Dataset will be created and shared pursuant to a Data Use Agreement appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jan 2030, 41 months after the start.
Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 41 months is above that.
Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Oct 2026 → Aug 2026, primary completion Jun 2030 → Jan 2030 and completion Oct 2031 → May 2031.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →